Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH phase 3 losmapimod study in facioscapulohumeral muscular dystrophy
NL-OMON58715Phase 3Completed
- Sponsor
- Fulcrum Therapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) (3 arms), sponsored by Fulcrum Therapeutics. Primary endpoints: Change from baseline in average total RSA Q1-Q5 with 500 g wrist weight at Week 48 and Long-term safety and tolerability. Started Sep 2022; status: completed.
02
Drugs
losmapimod
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON58715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58715.